AU622417B2 - Creation of Inventions and Patents with Artificial Intelligence

AU622417B2 – Human anti-rh(d) monoclonal antibodies
– Google Patents

AU622417B2 – Human anti-rh(d) monoclonal antibodies
– Google Patents
Human anti-rh(d) monoclonal antibodies

Download PDF
Info

Publication number
AU622417B2

AU622417B2
AU23895/88A
AU2389588A
AU622417B2
AU 622417 B2
AU622417 B2
AU 622417B2
AU 23895/88 A
AU23895/88 A
AU 23895/88A
AU 2389588 A
AU2389588 A
AU 2389588A
AU 622417 B2
AU622417 B2
AU 622417B2
Authority
AU
Australia
Prior art keywords
monoclonal antibody
cells
antibody
reagent
monoclonal
Prior art date
1987-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU23895/88A
Other versions

AU2389588A
(en

Inventor
Benjamin Arthur De Burgh Bradley
Alan Doyle
Belinda Mary Kumpel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

National Blood Authority

Original Assignee
Central Blood Laboratories Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1987-09-18
Filing date
1988-09-16
Publication date
1992-04-09

1987-09-18
Priority claimed from GB878722019A
external-priority
patent/GB8722019D0/en

1988-09-16
Application filed by Central Blood Laboratories Authority
filed
Critical
Central Blood Laboratories Authority

1989-04-17
Publication of AU2389588A
publication
Critical
patent/AU2389588A/en

1992-04-09
Application granted
granted
Critical

1992-04-09
Publication of AU622417B2
publication
Critical
patent/AU622417B2/en

1994-11-24
Assigned to NATIONAL BLOOD AUTHORITY
reassignment
NATIONAL BLOOD AUTHORITY
Alteration of Name(s) in Register under S187
Assignors: CENTRAL BLOOD LABORATORIES AUTHORITY

2008-09-16
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2317/00—Immunoglobulins specific features

C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

C07K2317/77—Internalization into the cell

Description

AU-AI-23895/88′ P WOQ IN E\L Pl p’ERTYORGANIZATION T R T t 0aoi Burel 7 INTERNATIONAL APPLICATION PUBLISHE UN ER TE P t ENT COOPERATION TREATY (PCT) (51) International Patent Classification 4 (11) International Publication Number: WO 89/ 02600 GOIN 33/80, C12P 21/00 Al A61K 39/395, C12N 15/00, 5/00 (43) International Publication Date: 23 March 1989 (23.03.89) (21) Internationrl Application Number: PCT/GB88/00756 (74) Agents: HOLMES, Michael, John et al.; Frank B.
Dehn Co., Imperial House, 15-19 Kingsway, Lon- (22) International Filing Date: 16 September 1988 (16.09.88) don WC2B 6UZ (GB).
(31) Priority Application Number: 8722019 (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (Euro- (32) Priority Date: 18 September 1987 (18.09.87) pean patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (Eu- (33) Priority Country: GB ropean patent), NL (European patent), SE (European patent), US.
(71) Applicant (for all designated States except US): CEN- TRAL BlOOD LABORATORIES AUTHORITY Published [GB/GB]; Dagger Lane, Elstree, Borehamwood, Hert- With international search report.
fordshire WD6 3BX (GB).
(72) Inventors; and Inventors/Applicants (for US only) DE BURGH BRADLEY, Benjamin, Arthur [GB/GB]; Follybrook Cottage, 12 Bury Hill, Winterbourne Down BS17 A..JP. 25 MAY 1989 IAD DOYLE, Alan [GB/GB]; 12 Falcons Way, Salisbury SP2 8NR KUMPEL, Belinda, Mary AUSTRALIAN [GB/GB]; Woodside, Wrington Road, Congresbury, Bristol BS19 5AR 17 APR 1989 PATENT OFFICE (54) Title: HUMAN ANTI-Rh(D) MONOCLONAL ANTIBODIES (57) Abstract The present invention provides human monoclonal antibodies having the following essential characteristics: exhibiting activity against Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; being IgG3 proteins; having kappa light chains; being of the allotype G3m(21); exhibiting activity against Du cells by an indirect antiglobulin test; exhibiting activity against D i v
D
v and DTar variant antigens; and being inactive against DVI or DB variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent haemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibody of cell line ECACC 86091606 deposited at the European Collection of Animal Cell Cultures, Porton Down, U.K. on 16th September 1987.
r.
I
F
i
E
1 j t
:BI
I:
i: P WO 89/02600 PCT/GB88/00756 -1- Human Anti-Rh(D) Monoclonal Antibodies The present invention relates to human monoclonal antibodies to the Rh(D) antigen of human red blood cells. In particular, it relates to such antibodies of the IgG3 sub-class which may be used to detect not only the normal Rh(D) antigen on either D-positive or “weak D” or D u cells, but also important variants of the Rh(D) antigen.
Of the antigens of the so-called Rh blood group system, the Rh(D) antigen is responsible for some of the most severe reactions following transfusion to a patient with corresponding antibody.
Since an Rh(D-) individual with anti-Rh(D) who receives Rh(D+) blood is liable to suffer substantial red blood cell (RBC) destruction due to the Rh(D) phenotype incompatibility, blood of donors and blood transfusion recipients is routinely classified as Rh(D+) or Rh(D-) by agglutination tests with anti-Rh(D) antibody. The Rh phenotype of RBCs is commonly further defined with reference to the Fisher-Race system, which is based on the assumption that the inheritance of the Rh antigens is determined by three pairs of allelic genes, C-c, D-d and E-e, acting at very closely linked loci. According to this theory, a person may inherit a set of three Rh genes from each of his parents C or c, (ii) D or d, (iii) E or e (no d antigen has as yet been identified, but the symbol is used to indicate the presence of a gene, allelic to the D gene, which does not produpe D antigen). For example, an Rh(D+) person may inherit CDe from one parent and cde from the other. The frequencies of the commonest Rh gene combinations as determined with t IR g WO 89/02600 PCT/GB88/00756 2 reference to the Fisher-Pace system for an English population, together with the ‘short symbols’ which are used, particularly in speech, are given in Table 1 below.
Table I Frequency of common Rh genes for an English Population Short symbol CDE nomenclature Frequency
R
1 CDe 40.8 r cde 38.9
R
2 cDE 14.1 RO cDe 2.6
R
1 w CwDe 1.3 cdE 1.2 r’ Cde 0.01 RZ CDE rarer r CdE RN (C)D(e) Despite expansion over the years, the Fisher- Race system has not been adequate to account for all the reactions that have been observed with the Rh system (Mollison, P.L. (1983) Blood Transfusion In Clinical Medicine, 7th edn., Blackwell Scientific, Oxford). Nevertheless, the World Health Organisation has recommended that in the interest of simplicity I and uniformity this nomenclature should be universally adopted and all Rh genotypes given hereinafter are defined on the basis of the conventional Fisher- Race system.
In addition to the need for anti-Rh(D) antibody for Rh-typing of RBCs, such antibody is also importantly required for passive-immunisation of Rh(D-) mothers to prevent haemolytic disease of the newborn (HDN).
This condition arises in newborn Rh(D+) infants of Rh(D-) mothers previously sensitized to Rh(D) ‘i WO 89/02600 PCT/GB88/00756 -3antigen as a result of IgG anti-Rh(D) antibodies crossing the placenta during pregancy and causing foetal RBC destruction. Sensitization of the Rh(D-) mother to Rh(D) antigen may have occurred at the birth of an earlier Rh(D+) child due to some foetal RBCs entering the maternal circulation and being recognised by the maternal immune system. To reduce the incidence of HDN, it is routine practice in the United Kingdom and many other countries to give anti-Rh(D) antibodies to Rh(D-) mothers immediately after the birth of an Rh(D+) infant so that any Rh(D+) RBCs which have entered the maternal circulation are rapidly removed (Mollison, P.L. (1983) loc.
cit.; Laros Jr., R.K. (1986), “Erythroblastosis Fetalis” in “Blood Group Disorders In Pregnancy”, Ch. 7, p. 103).
At the present time, anti-Rh(D) antibody for use in both Rh-typing of RBCs and passive immunisation of Rh(D-) mothers is largely obtained directly from female donors immunised during pregnancy or from immunised male volunteers. The success of the programme of post-partum prophylactic administration of human anti-Rh(D) immunoglobulin to Rh(D-) women has, however, resulted in a dramatic reduction in the number of naturally alloimmunised women (Urbaniak, “RhD haemolytic disease of the newborn: the changing scene”, Br. Med. J. (1985) 291, Also, deliberate immunisation of individuals with Rh(D+) RBCs carries the risks common to receiving any transfusion of RBCs,e.g. risk of transmission of hepatitis viruses and HIV. Hence, there is much interest in obtaining human monoclonal anti- Rh(D) antibodies for both diagnostic and therapeutic purposes.
As stated above, in routine blood testing, blood types are divided into Rh(D+) and Rh(D-) on the basis of the apparent presence or absence I i fl~l_ __i WO 89/02600 PCT/GB88/0075 6 4 of Rh(D) antigen on the RBCs as indicated by agglutination tests with anti-Rh(D). However, a small number of persons with apparently Rh(D-) blood have RBCs that are not directly agglutinated by anti-Rh(D) during such routine testing, but that do react when the D-typing test is performed using selected anti-Rh(D) reagents by the indirect antiglobulin test. Cells thus identified are designated Du The frequency of the D u phenotype is about 0.2% overall, 0.6% among Caucasians, and about of all Rh(D-) gravid women. At least three different mechanisms may be responsible for the expression of the Du phenotype: hereditary absence’of a portion of the complete Rh(D) antigen, gene interaction with suppression of D by C in the trans position, and a D gene producing a weak antigen.
In the early 1950s, reports first appeared of the presence of anti-Rh(D) in individuals of the Du phenotype following blood transfusion with Rh(D+) blood or pregnancy resulting in the birth of a Rh(D+) infant. It later became apparent that in some individuals whose blood is classified Rh(D+).
parts of the Rh(D) antigen are missing from the RBCs. When exposed by transfusion or pregnancy to Rh(D+) RBCs carrying the complete Rh(D) antigen, persons carrying an incomplete Rh(D) antigen on their RBCs are capable of making alloanti-D against the Rh(D) antigen portion they lack. The blood of such individuals is called D variant when the RBCs react directly with routine anti-Rh(D) reagents or Du variant when the cells react only by the indirect antiglobulin technique.
The observation that allo anti-Rh(D) can be produced in patients who have Rh(D+) RBCs has led to common usage of the term “D mosaic” to describe the Rh(D) antigen in its complete native form.
Routine anti-Rh(D) reagents generally cannot differentiate I ir l i 1 1 c a6 i 5 h C’ those RBCs that lack part of the l mosaic from those that have all the D components. The D variant phenotypes have been categorised by Tippett and Sanger (Vox. Sang. (1962)7, 9-13). This system is based on the interaction of RBCs and serum from D- and D u variant individuals. The seven categories (see Table II below) allow for expansion; subdivisions are already recognised in categories III, IV and V. Categories I and II have been found to have so many similarities that they are now generally considered as a single sub-group.
Table II Tippett and Sanger categories for D- or Du positive blood with anti-Rh(D) Category Racial origin Usual haplotype I White DCe
II
IIIa Black IIIb Usually Black Dce IIIc White IVa Mostly Black, some White IVb White Dce Va Black and White Vb White DuCe Vc Black and White VI Nearly all White DuCe VII White DCe An alternative, but lesser used, classification by Wiener uses letters A,B,C,D instead of Roman Numerals. Although there is no direct correlation between the two systems, it is often considered that D B and D V 1 are interchangeable.
Although the frequency of D and D u variant individuals within the human population is relatively RA4/. low, the total number of individuals of these blood L^o 3, V, ‘l^ WO 89/02600 PCT/GB88/00756 6 types who potentially have some risk of effective anti-Rh(D) formation as a result of exposure by blood transfusion or pregnancy to non-variant Rh(D+) cells is far from insignificant. Moreover, in addition to Rh(D-) women who give birth to Rh(D+) or Du infants, Du variant women who give birth to an Rh(D+) infant may also benefit from postpartum anti-Rh(D) treatment to reduce the risk of HDN (White, C.A. et al. (1983) Am. J. Obste!:.
Gynecol. 145, 1069-1073). Anti-sera capable of distinguishing D and Du variant RBCs are not widely available. Hence, provision of anti-Rh(D) monoclonal antibodies with a range of binding specificities for D and Du variant RBCs is seen as useful in enabling the more ready identification and categorisation of individuals possessing such cells (especially D or Du variant pregnant females who are suitable candidates for prophylactic anti-Rh(D) treatment) as well as for providing further structural information on the Rh(D) antigen complex.
Human monoclonal anti-Rh(D) antibody production has previously been achieved by:directly cloning Epstein Barr virus transformed B lymphocyte cell lines (hereinafter referred to as EBV-transformed LCL) derived from B lymphocytes of anti-Rh(D) positive donors (see GB-A 2127434; SCrawford et al. (1983) Lancet 1, 386-388 and Paire et al (1986) Immunol. Lett. 13, 137-141), cloning hybridoma cell lines formed by fusing anti-Rh(D) producing, EBV-transformed LCL with mouse, mouse-human or human myeloma cell lines (see co-pending British application no. 8709748, Thompson et al. (1986) Immunol. 58, 157-160 and EP-A-0162918), or by fusion of a human LCL with immune B cells (Lowe et al (1986) Vox. Sang. 51, 212-216).
-7- By cloning EBV-transformed LCL from anti- Rh(D) positive donors, we have been able to obtain, however,.monoclonal anti-Rh(D) antibodies of the IgG class which have a particularly useful binding specificity spectrum not shown for any previously disclosed anti-Rh(D) monoclonal antibody reagent.
According to the present invention, we provide human monoclonal antibodies having the following essential characteristics: exhibiting activity against Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; being IgG3 proteins; having kappa light chains; being of the allotype G3m(21); j exhibiting activity against D cells by an indirect antiglobulin test; exhibiting activity against D D and DI variant antigens; and being inactive against D or D variant antigens.
and antigen-binding fragments thereof.
In addition, monoclonal antibodies of the invention have been shown to exhibit activity against
=N
the R antigen.
Such monoclonal antibodies can be employed as routine anti-D reagents to classify RBCs as D-positive, Du or D-negative. For this purpose, a monoclonal antibody of the present invention may be employed either alone or in combination with one or more further anti- Rh(D) antibodies, preferably monoclonal antibodies, having one or.
more additional binding specificities. Thus, for example, a monoclonal antibody of the present invention may be advantageously blended with a further monoclonal antibody capable of binding the DI variant to provide an anti-Rh(D) reagent of broader specificity 7 8 present invention may, for example, be combined with an IgGl monoclonal antibody of the type disclosed in our co-pending International application (Publication No.
W089/02443) of even date herewith having the following binding characteristics: exhibiting activity against Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; V VII VI exhibiting activity against D D D and
D
B variant antigens; and being substantially non-reactive with I non-papain treated DI cells in an IAG test.
15 Amongst such antibodies, particularly preferred for use in combination with an anti-Rh(D) monoclonal antibody of the present invention is the monoclonal antibody designated B7 deposited at the European Collection of Animal Cell Cultures, Porton Down, U.K.
20 under accession No. ECACC 87091603 on 16th September 1987.
If monoclonal antibodies of the present invention are used for Rh-typing in parallel with an anti-Rh(D)
VI
reactive against D variants, eg. an appropriate 25 polyclonal anti-Rh(D) serum, those blood samples giving a positive result in an agglutination test with the latter, but negative results with a. monoclonal antibody of the invention can be predicted to be mainly or entirely of the D VI category (since this is virtually the only D variant antigen against which the new monoclonal antibodies are inactive). It has been established that amongst individuals classified as Rh(D+) or D u by a conventional agglutination test, but who are capable of making anti-D, a high percentage have
VI
the D variant antigen (Mollison, P.L. (1983) in “Blood Transfusion In Clinical Medicine”, I 1 t 9 Ch. 8, p 339). One use of the monoclonal antibodies of the invention is, indeed, in investigating the incidence of individuals of the DVI type in the population.
A monoclonal antibody of the present invention may also be of particular value for use in an anti- Rh(D) typing reagent to supplement the specificity of an anti-Rh(D) with no or only weak anti-Du activity, i.e. insufficient activity against D u cells to be able to reliably distinguish such cells from D-negative cells in a conventional agglutination test. Indeed, under FDA regulations in the U.S.A.
governing commercial anti-Rh(D) typing reagents, it is obligatory for such a reagent to be able to distinguish Du RBCs from truly D-negative RBCs.
Especially preferred amongst combination anti-Rh(D) reagents of the present invention are such reagents satisfying the above condition wherein an IgG anti- Rh(D) of the invention is employed together with an IgM anti-Rh(D) with only weak D u activity, e.g.
an IgM monoclonal anti-Rh(D) selected from the monoclonal IgMs of the deposited hybridoma cell lines MAD-2 (ECACC 86041803) and FOM-1 (ECACC 87021301), which form inter alia, the subject matter of published European Patent Application 0251440.
Such a reagent will advantageously be further complemented with at least one further IgG monoclonal anti-Rh(D) antibody which individually exhibits activity with u 3 D red cells by the indirect antiglobulin test, such that the blended reagent reacts by the same test with D D IV D and D V I cells. When Rh typing is carried out with such a reagent, D-positive cells will firtly be directly agglutinated by the IgM anti-Rh(D). The remaining non-agglutinated cells (apparently D-negative) may then be subsequently divided into truly D-negative and D u cells by addition of conventional Coomb’s reagent for an indirect
SI
i1 9 WO 89/02600 PCT/GB88/00756 10 antiglobulin test, whereupon Du cells binding IgG antibody will be agglutinated and thus distinguished.
The monoclonal anti-Rh(D) antibodies of the invention can be made by conventional methods known for the production of monoclonal antibodies and in particular by the culture of EBV-transformed human B-lymphocytes selected on the basis of secretion of anti-Rh(D) immunoglobulin having the characteristics set out above for the required antibodies. The culture supernatants so produced constitute a further feature of the present invention.
We have now investigated in detail 5 cloned EBV-transformed LCL which produce IgG3 anti-Rh(D) monoclonal antibodies as defined above, hereinafter referred to as A4, A5, A6, A7 and A8. All these cloned cell lines were obtained by starting with peripheral B lymphocytes from a chosen anti-Rh(D) donor and employing the procedure described in GB-A 2145113 or a substantially similar procedure to establish and clone EBV-transformed LCL producing a monoclonal antibody of the desired specificity (see Example In continuous culture using RPMI- 1640 medium supplemented with 10% mycoplasma free-foetal calf serum, 0.2 mg/ml arginine and antibiotics to prevent mycoplasma growth, they have been found to be highly stable and to provide 1 a culture supernatant having an anti-Rh(D) titre, as determined by an indirect antiglobulin (IAG) assay in low ionic strength saline versus R 1
R
1 (CDe/CDe) RBCs, in the range 2000-16000. Such a culture supernatant is suitable for use in Rhtyping without the need for concentration and indeed, may be diluted for use.
Antibody production characteristics of the above-mentioned specific clones in continuous culture are summarised in Tables IIIa and IIIb below.
All these clones have been shown to maintain a 1 I 4 w i 1P: WO 89/02600 PCT/GB88/00756 11 stable titre over at least 8 months continuous culture. The degree of agglutination in IAG tests was graded in conventional manner on a scale 0 to 6.
Table IIIa IAG titre RBCs in low ionic
R
1 r cells 64-256 strength saline) R R 1 cells Rur cells Microtitre with bromelain-treated R 2
R
2 cells 2000-16000 32-256 8000-16000 Anti-Rh(D) (IU/ml) IgG (pg/ml) 2-12 1.1-2.8 j 1 a i ri i WO 89/02600 PCT/GB88/00756 12 Table IIIb culture A4 A5 A6 A7 A8 supernatant IAG reactivity of supernatant with 3% RBCs in low ionic strength saline.
(Grade: 0 to 6) i r: Red Cell Phenotype
R
1 1 6 6 6 6 Rur 6 6 5 5 r 6 6 16 RUr 6 6 6 6 o It was further found that those monoclonal antibodies of the invention that were tested reacted
S
with RBCs of phenotype R 2 rG-, hr-, R 1
R
z and R 2
R
z but are negative with r”Gr, r r, rG, r’r, hr r’r and Rh33+.
According to a still further aspect of the present invention, we thus provide a method of Rh-typing of RBCs wherein an aqueous solution of a monoclonal anti-Rh(D) immunoglobulin of the present invention is employed. The monoclonal immunoglobulin is preferably contained in a culture supernatant which may be used directly or, more usually, after dilution. As hereinbefore indicated, it may be desirable to blend an IgG3 antibody of the present invention with one or more further anti-Rh(D) monoclonal antibodies of different specificity, e.g. a further IgG antibody having anti-D V I activity. Suitable diluents include physiological saline or phosphate buffered saline advantageously containing bovine serum albumin and a surfactant or suspending agent such as Tween 80 or methyl cellulose.
I1 ILL .r i i WO 89/02600 PCT/GB88/00756 13 IgG3 anti-Rh(D) antibodies of the present invention are good promoters of binding and phagocytosis of Rh(D+) RBCs by monocytes and macrophages and hence are also of much interest from the point of view of providing effective prophylactic anti- D treatment for prevention of HDN. Indeed, culture supernatants of the cell lines A4 and A5 have been found in in vitro assays to induce greater rosetting and phagocytosis of sensitized RBCs by U937 monocytes than a conventional polyclonal anti-Rh(D) serum.
Moreover, the same culture supernatants are comparable to a conventional polyclonal anti-Rh(D) serum in mediating binding of sensitized RBCs to cultured macrophages derived from interferon-g stimulated monocytes. (see secti-ns (iii) and (iv) of Example 1) Thus, according to a further aspect of the present invention, we provide a monoclonal IgG3 antibody of the present invention for use in passive immunisation of an Rh(D-) or D or D u variant mother after the birth of an Rh(D+) child to prevent sensitisation of the mother to Rh(D) antigen. A sterile solution of such an antibody for human injection may be formulated in any physiologically acceptable aqueous medium, for example isotonic phosphate buffered saline or serum. Alternatively, the antibody may ‘be supplied in a freeze-dried formulation ready (for reconstitution prior to use. To provide a highly efficient prophylactic preparation for use in the prevention of HDN, a monoclonal anti-Rh(D) of the present invention may be employed with one or more further anti-RhD antibodies. For routine use, ideally an anti D V I antibody will be included.
An antibody of the present invention may also find use in a prophylactic preparation to complement an IgGl anti-Rh(D) monoclonal antibody
B
14 of our co-pending International application (Publication No W089/02442) of even date herewith claiming priority from GB-A-8722018, the contents of which are incorporated herein by reference.
A7 of the above-mentioned cloned EBV-transformed lymphocyte cell lines was deposited on 16th September 1987 at the European Collection of Animal Cell Cultures, Porton Down, U.K. under accession No. ECACC 87091606.
Further details of the preparation of this deposited cell line and the identifying characteristics of its continuous culture supernatant are provided in Example 1 of the following non-limiting examples.
S.
‘II
I- I I WO 89/02600 PCT/GB88/00756 EXAMPLE 1 Establishment and Cloning of Anti-Rh(D) Producing EBV-transformed LCL Sources of B Lymphocytes Donor A: female, immunised during her first and only pregnancy (which resulted in delivery of a normal Rh(D+) infant), boosted with 0.5 ml packed Rh(D+) (R 2 r) RBCs 4 years after parturition, and a peripheral blood sample obtained 8 days after boosting when her serum anti-D level was Establishment of cell lines Peripheral blood mononuclear cells from donor A were separated on Lymphoprep (Nyegaard and Co), incubated in the presence of EBV (1 ml culture supernatant from filtered mycoplasma free B95-8 cell line per 107 cells) at 37 0 C for 1 hour and washed in phosphate-buffered saline (PBS). Aliquots were plated at 0.5×10 6 cells/ml in 2 ml wells using lymphoblastoid cell culture medium (RPMI-1640 medium containing 10% mycoplasma free foetal calf serum (FCS), 0.2 mg/ml arginine, 100 IU/ml penicillin (Glaxo), 50 pg/ml streptomycin (Glaxo), 25 IU/ml polymixin (Glaxo), 25 pg/ml kanamycin (Gibco), pi/ml fungizone (Squibb), 25 pg/ml gentamycin sulphate (Sigma) and 20 pg/ml trobicin (UpJohn)), supplemented with either 1% phytohaemagglutinin (PHA) or 0.5 pg/ml cyclosporin A (CsA), above a feeder layer of mouse peritoneal macrophages.
All the cultures were subsequently incubated at 37 0 C in 5% CO2, 95% humidified air. Medium changes were performed every 3 to 4 days and, after 3 weeks culture, the cells were transferred to
:I
1 “i7 WO 89/02600 PCT/GB88/00756 -16ml flasks. All the cell lines were enriched by rosetting at 3-4 weekly intervals.
Cloning Cells were plated out at limiting dilution at 5 and 10 cells per well in flat bottomed 96well plates over a feeder layer of mouse peritoneal macrophages (Doyle et al. (1985) Human Immunology 13, 199-209). Cultures were fed once a week and after 3-4 weeks cloned cells positive for anti- D were grown up.
Derivation of clones The donor A polyclonal cell line giving rise to the clone A4 was initiated with PHA and sequentially enriched for anti-Rh(D) positive cells by rosetting 13 times before cloning.
Four further clones producing anti-Rh(D) antibody of the IgG3 sub-class (designated A6, A7 and A8) were derived from lymphocytes from clone A4.
Clones A5, A6 and A7 were erroneously designated B4, B5 and B6 respectively in the priority application (GB-A 8722019). The results of tissue type and karotype analysis of the above-selected cell lines are set out in Table IV below.
j LL -i C i WO 89/02600 PCT/GB88/00756 17 Table IV Cell Line A5 A6 A7 A8 Donor A sex Female Tissue Type HLA: A 2,w19 B 44,35 DR Karotype sex chromosomes xx ploidy some diploid cells, some tetraploid cells markers 12p 22p Quantitation of anti-Rh(D) activity and IgG in culture supernatants Anti-Rh(D) activity in the supernatants was quantified against British national standards by Auto Analyser. The mean of at least two determinations was calculated. The quantitative estimation of IgG was performed by ELISA (modification of the method of Wakefield et al. in Clin. Chim. Acta.
(1982) 123, 303-310) with at least eight determinations for each supernatant. Coating antibody (affinity purified goat anti-human IgG (Sigma)) was used at 1/200 in 0.05M carbonate buffer pH 9.6. Supernatants and standard (purified human IgG (Sigma)) were diluted in RPMI 1640 10% FCS. Peroxidase-conjugated goat anti-human IgG (Sigma) was diluted 1/500 in PBS 0.05% Tween 20 and the substrate was TMB 5,5’-tetramethyl benzidine).
18 Not all the cell lines established under different experimental conditions showed stable antibody production. However, all the cell lines which were subsequently cloned had maintained high titres (over 1/33,000 by microtitre) of anti-Rh(D) for over 6 months.
All clones from these cell lines were positive for anti-Rh(D) and maintained their titres throughout the duration of continuous culture in the case of A4 for over 2 years). The doubling time was 3-7 days. The cells grew well in suspension culture with no loss of antibody production.
Immunoglobulin class and subclass determination An immunodot assay (McDougal et al. (1983) J. Imm.
Meth. 63, 281-290) was used to determine the reaction of the monoclonal anti-Rh(D) antibodies absorbed to nitrocellulose with anti-IgG, anti-IgM, anti-kappa and anti-lambda antiserum (Serotec); positive reactions were 20 detected with proxidase-conjugated anti-sheep IgG (Serotec) followed by colour development with 4-chloro-l-naphthol. The IgG subclass was evaluated by agglutination of anti-D coated RBCs by monoclonal anti-subclass antibodies (Unipath).
SDS-Page and Western Blotting Iscove’s supernatants (serum free) were electrophoresed under reducing conditions on polyacrylamide gels (Laemmli, Nature (1970) 227, 680-685). The separated proteins were then electrophoretically transferred to nitrocellulose membranes (Burnette, Annals Biochem. (1981) 112, 195-203), which were probed with anti-IgG antiserum (Serotec) and detected as above.
The monoclonal antibodies of the cell lines A6 and A7 were all found to have a heavy RA4/ .1 V .anisbcasanioie Uipt) D 19 chain of molecular weight approximately 61,000 Daltons.
Protein A absorption 2 ml volumes of supernatants were run twice down a 25mm (iml) column of Protein A sepharose C1-4B (Sigma) and absorption of anti-D assessed by titration. The anti-Rh(D)s of the selected cell lines were not absorbed by Protein A, as expected for immunoglobulins of the IgG3 subclass.
Gm allotyping RBCs were coated with the monoclonal anti- Rh(D) antibodies and agglutination assessed using panels of Gm allotyping reagents (Birmingham or Amsterdam).
(ii) Serology Culture supernatants from continuous cultures of the selected cell lines were tested by the IAG test using rabbit anti-human IgG and using 3% R R 1 ,R r u u R r or R r cells in low ionic strength saline (see 1 0 Tables IIIa and IIIb). The same supernatants were also tested against a panel of D variant RBCs under the same conditions (see Table V below). The B degree of agglutination was graded in conventional I manner on a scale 0 to 6.
L *B p T? ^ir 20 Table V Reaction of monoclonal anti-Rh(D) antibodies with “partial” D positive red cells using IAG
I
Culture A4 A5 A6 A7 supernatant (Grade: 0 to 6) DIV 5 5 6 6
D
V 5 5 6 6 DVII 5 5 6 6 DVI 0 0 0 0 DB 0 0 0 0 (iii) U937 Monocyte rosetting and phagocytosis assay 100ul packed OR 1
R
2 RBCs were sensitised with 500ul anti-D (previously adjusted to lug/ml) at 370 for 60 minutes, washed and resuspended at 1 x 10 cells/ml in RPMI. U937 cells were taken in the log phase of growth arn cultured for two days either in the presence or absence of interferonq 6 (Amersham) at 50 U/ml. 45 x 10 red cells were then added to a pellet of 1.5 x 106 U937 cells and mixed, giving a ratio of 30:1. For the rosetting asay, the cells were incubated at room temperature for 5 minutes, spun at 600 rpm for 3 minutes and examined in a haemocytometer after a further 5minutes. Phagocytosis was assessed immediately after incubating the cells at 370 for 3 hours.
Results were expressed as the percentage of monocytes with one or more adherent or phagocytosed red cells.
A comparision of the results obtained wth culture supernatants of clones A4 and A5 and a conventional polyclonal anti-Rh(D) serum is given in Figures f ii; r ,.1
I
i a r a t I i i f iI :i WO 89/02600 PCT/GB88/00756 21 1 and 2. Red cells sensitised with culture supernatant from clone A8 formed rosettes with 100% of U937 cells (cultured in the absence of interferon-6 (iv) Macrophage binding assay RBCs (R 2 r) (1 volume) were sensitised with monoclonal anti-Rh(D) (2 volumes of untreated culture supernatant) and incubated with monocyte-derived cultured macrophages. The macrophages were stimulated with 500 U/ml of recombinant immune interferon (Biogen, Geneva) during the 48 hours prior to their use in the assay. The binding of RBCs to macrophages was assesed microscopically and expressed as the macrophage binding index number of red cells attached to or ingested by 100 macrophages).
Table VI below shows the results obtained with culture supernatants of clones A4 and The ability of these supernatants to bring about red cell-macrophage interaction was similar to that of the polyclonal anti-Rh(D), which served as a positive control.
Table VI it Source of culture culture Polyclonal anti-D supernatant supernatant anti-Rh(D) A4 A5 serum Macrophage binding index 480 472 416-500 anti-Rh(D)(IU/ml) 2 12 43
I
I
i.
a Ij i i :1: i:t ilr S Ci t I F WO 89/02600 PCT/GB88/00756 22 Lymphocyte ADCC assay The culture supernatants of clones A4, A7 and A8 were tested in a lymphocyte antibody -directed cell cytoxicity (ADCC) assay.
Equal volumes (50pl) of target cells (chromium- 51 labelled R 1
R
1 RBC suspension), effector cells (K lymphocytes) and anti-Rh(D) culture supernatant were incubated overnight at 37 0 C in microplates after mild centrifugation and the chromium -51 release measured (Urbaniak (1979) Br.J. Haematol.
42, 303-314). The effector: target call ratio was 15:1.
None of the culture supernatants tested were found to exhibit significant ADCC activity (see Table VII below).
Table VII 4
!I
a: Monoclonal antibody A4 A5 A7 A8 Anti-Rh(D) serum.
specific lysis.
Effector KF -2 1 0 Effector BW 4 0 0 92 Effector TJ 0 not determined i. i

Claims (9)

1. A human monoclonal antibody having the following essential characteristics: exhibiting activity against Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; being IgG3 proteins; having kappa light chains; being of the allotype G3m(21); exhibiting activity against DU cells by an indirect antiglobulin test; IV V VII S(f) exhibiting actn ivity against D D and D t variant antigens; and being Inci Deisi; and antigen-binding fragments thereof. I.

2. The monoclonal antibody of claim 1 produced by the cell line ECACC 87091606. 3 3. An anti-Rh(D) reagent wherein a monoclonal antibody S* a monoclonal antibody capable of binding the D variant is present.

5. An anti-Rh(D) reagent as claimed in claim 3 wherein the antibody component comprises: a monoclonal antibody as defined in claim 1, an IgM anti-Rh(D) with no or only weak anti- D u activity. ad n n s 25 v L -I i -I El 24

6. An anti-Rh(D) reagent as claimed in claim wherein the antibody component additionally comprises an IgG monoclonal anti-Rh(D) capable of exhibiting activity against D red cells in an indirect antiglobulin test.

7. An anti-Rh(D) reagent as claimed in claim 5 or claim 6 wherein component is selected from the monoclonal IgMs of the deposited hybridoma cell lines MAD-2 (ECACC 86041803) and FOM-1 (ECACC 87021301).

8. A human lymphocyte-derived cell line capable of producing a monoclonal antibody as claimed in claim 1.

9. The cell line of claim 8 deposited at the European S 15 Collection of Animal Cell Cultures under accession No. ECACC 87091606. S* 10. A monoclonal antibody as claimed in claim 1 or claim 2 for use in passive immunisation to prevent 20 haemolytic disease of the newborn. S” 11. A culture supernatant obtained by cultivation of a cell line as claimed in claim 8 or claim 9. r: 25 12. A pharmaceutical composition for use in passive immunisation to prevent haemolytic disease of the newborn comprising a monoclonal antibody as claimed in claim 1 or claim 2 in association with a physiologically acceptable carrier or diluent.

13. A pharmaceutical composition as claimed in claim 12 wherein the antibody component additionally comprises a monoclonal antibody capable of binding the D VI variant. -ABI I q3i

14. A method of Rh- i j> ::9 25 typing wherein a monoclonal antibody as claimed in claim 1 or claim 2 or an anti-Rh(D.) reagent as claimed in any one of claims 3 to 7 is employed, said monoclonal antibody or said reagent being in the form of an aqueous solution. t “h I 1~ ll .i i-1 ra”i ri i* (p rl-~l I I ii 1 _1 I 1_1. i: I

AU23895/88A
1987-09-18
1988-09-16
Human anti-rh(d) monoclonal antibodies

Expired

AU622417B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

GB878722019A

GB8722019D0
(en)

1987-09-18
1987-09-18
Human anti-rh(d)monoclonal antibodies

GB8722019

1987-09-18

PCT/GB1988/000756

WO1989002600A1
(en)

1987-09-18
1988-09-16
HUMAN ANTI-Rh(D) MONOCLONAL ANTIBODIES

Publications (2)

Publication Number
Publication Date

AU2389588A

AU2389588A
(en)

1989-04-17

AU622417B2
true

AU622417B2
(en)

1992-04-09

Family
ID=26292756
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU23895/88A
Expired

AU622417B2
(en)

1987-09-18
1988-09-16
Human anti-rh(d) monoclonal antibodies

Country Status (1)

Country
Link

AU
(1)

AU622417B2
(en)

Cited By (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU645263B2
(en)

1989-09-01
1994-01-13
National Blood Authority
Modified human Anti-Rh(D) antibodies

AU647054B2
(en)

1989-11-13
1994-03-17
National Blood Authority
Monoclonal antibodies

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU2521288A
(en)

1987-09-18
1989-04-17

National Blood Authority

Human anti-rh(d) monoclonal antibodies

AU2383288A
(en)

1987-09-18
1989-04-17

Central Blood Laboratories Authority

Human anti-rh(d) monoclonal antibodies

AU607134B2
(en)

1986-04-25
1991-02-28

Central Blood Laboratories Authority

Human anti-rhesus D producing heterohybridomas

1988

1988-09-16
AU
AU23895/88A
patent/AU622417B2/en
not_active
Expired

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU607134B2
(en)

1986-04-25
1991-02-28
Central Blood Laboratories Authority
Human anti-rhesus D producing heterohybridomas

AU2521288A
(en)

1987-09-18
1989-04-17
National Blood Authority
Human anti-rh(d) monoclonal antibodies

AU2383288A
(en)

1987-09-18
1989-04-17
Central Blood Laboratories Authority
Human anti-rh(d) monoclonal antibodies

Cited By (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU645263B2
(en)

1989-09-01
1994-01-13
National Blood Authority
Modified human Anti-Rh(D) antibodies

AU647054B2
(en)

1989-11-13
1994-03-17
National Blood Authority
Monoclonal antibodies

Also Published As

Publication number
Publication date

AU2389588A
(en)

1989-04-17

Contact information